Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
Dellota, Exequiel A
Dillen, Josh R
Gupta, Ravindra K
Public Library of Science (PLoS)
MetadataShow full item record
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., et al. (2022). Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. PLoS One, 17 (2) https://doi.org/10.1371/journal.pone.0263328
Funder: Swiss Kidney Foundation
Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy.
CHO Cells, Animals, Humans, Cricetulus, Immunoglobulin G, Neutralization Tests, Vaccination, Renal Dialysis, Risk Factors, Case-Control Studies, Follow-Up Studies, Antibody Affinity, Dose-Response Relationship, Immunologic, Antibodies, Neutralizing, HEK293 Cells, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines
MRC (via Imperial College London) (MR/W005611/1)
External DOI: https://doi.org/10.1371/journal.pone.0263328
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334948
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/